Literature DB >> 18208872

The association of multiple sclerosis and Hodgkin's disease: the role of Epstein-Barr virus infection.

Mario Habek1, Vesna V Brinar, Sanja Hajnsek.   

Abstract

The aetiology of multiple sclerosis (MS) is still an unresolved question. Several recently reported studies are implicating Epstein-Barr virus (EBV) as one of the key players in MS pathogenesis. We present a 21-year-old male patient with a history of EBV-related infectious mononucleosis in puberty and Hodgkin's disease two years previously treated with irradiation and chemotherapy. The patient presented with spastic paraparesis that resolved promptly on corticosteroid treatment. There were no signs of Hodgkin's disease relapse. In the next three years he had three more bouts of the disease and he was diagnosed with relapse-remitting MS. There is evidence of EBV involvement in MS pathogenesis; the association of MS with EBV-related infectious mononucleosis and Hodgkin's disease being just one of them. Although there are many unanswered questions, it is clear that without EBV seropositivity MS in adults is extremely rare.

Entities:  

Mesh:

Year:  2008        PMID: 18208872     DOI: 10.1177/1352458507082600

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Paraneoplastic syndromes associated to Hodgkin's lymphoma.

Authors:  Javier Munoz; Wilfredo Romero; Amr Hanbali; Philip Kuriakose
Journal:  BMJ Case Rep       Date:  2011-12-13

2.  Expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) in tumor cells.

Authors:  Martin S Staege; Katja Müller; Stefanie Kewitz; Ines Volkmer; Christine Mauz-Körholz; Toralf Bernig; Dieter Körholz
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

3.  Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.

Authors:  Isabel Blancas; Nuria Cárdenas; Mayte Delgado; Jose Miguel Jurado; Marta Legeren; Ana Villaescusa; Fernando Galvez; Marisol Yelamos
Journal:  Oncol Lett       Date:  2014-09-10       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.